Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 5/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | PRNP | P04156 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.41 |
| ▸ | RAB9A | P51151 | 5/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.41 |
| ▸ | RELA | Q04206 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20504504 | 0.85 | MGAM (0.44) | MGAMMAPTALDH1A1GAAHPGD | |
| SCHEMBL16449537 | 0.83 | KMT2A (0.48) | MGAMMAPTALDH1A1GAAHPGD | |
| SCHEMBL1613313 | 0.83 | MGAM (0.43) | MGAMMAPTALDH1A1GAAHPGD | |
| SCHEMBL9033949 | 0.81 | MGAM (0.47) | MGAMMAPTALDH1A1GAAMEN1 | |
| SCHEMBL28667841 | 0.81 | MEN1 (0.46) | MGAMMAPTALDH1A1GAAHPGD | |
| SCHEMBL294784 | 0.79 | MGAM (0.53) | MGAMMAPTALDH1A1GAAMEN1 | |
| SCHEMBL4831623 | 0.78 | CYSLTR2 (0.40) | MGAMMAPTALDH1A1GAAHPGD | |
| SCHEMBL28669059 | 0.78 | MEN1 (0.48) | ALDH1A1HPGDMEN1KMT2AKDM4E | |
| SCHEMBL31140011 | 0.77 | MGAM (0.47) | MGAMMAPTALDH1A1GAAMEN1 | |
| SCHEMBL2316635 | 0.77 | MGAM (0.47) | MGAMMAPTALDH1A1GAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4057813-A1 | COMPOSITIONS AND METHODS FOR TREATING HUANGLONGBING DISEASE IN CITRUS | New Life Crop Sciences LLC (US) | 2022-09-21 | — | — | EP | claimed |
| CN-114980736-A | Compositions and methods for treating citrus greening disease | 新生命作物科学有限责任公司 | 2022-08-30 | — | — | CN | claimed |
| US-20210144998-A1 | COMPOSITIONS AND METHODS FOR TREATING HUANGLONGBING DISEASE IN CITRUS | NEW LIFE CROP SCIENCES LLC | 2021-05-20 | — | — | US | claimed |
| WO-2021097410-A1 | COMPOSITIONS AND METHODS FOR TREATING HUANGLONGBING DISEASE IN CITRUS | NEW LIFE CROP SCIENCES LLC (US) | 2021-05-20 | — | — | WO | claimed |
| EP-3808348-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) | Biogen MA Inc. (US) | 2021-04-21 | — | — | EP | claimed |
| US-20130183289-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) | BIOGEN IDEC MA INC (US) | 2013-07-18 | — | — | US | claimed |
| WO-2011029053-A1 | HUMAN EMBRYONIC STEM CELLS FOR HIGH THROUGHOUT DRUG SCREENING | BUCK INSTITUTE FOR AGE RESEARCH (US) | 2011-03-10 | — | — | WO | claimed |
| EP-2200611-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) | Biogen Idec MA, Inc. (US) | 2010-06-30 | — | — | EP | claimed |
| WO-2009038684-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) | BIOGEN IDEC MA INC. (US) | 2009-03-26 | — | — | WO | claimed |
| EP-4057813-A1 | COMPOSITIONS AND METHODS FOR TREATING HUANGLONGBING DISEASE IN CITRUS | New Life Crop Sciences LLC (US) | 2022-09-21 | — | — | EP | disclosed |
| CN-114980736-A | Compositions and methods for treating citrus greening disease | 新生命作物科学有限责任公司 | 2022-08-30 | — | — | CN | disclosed |
| WO-2021097410-A1 | COMPOSITIONS AND METHODS FOR TREATING HUANGLONGBING DISEASE IN CITRUS | NEW LIFE CROP SCIENCES LLC (US) | 2021-05-20 | — | — | WO | disclosed |
| US-20210144998-A1 | COMPOSITIONS AND METHODS FOR TREATING HUANGLONGBING DISEASE IN CITRUS | NEW LIFE CROP SCIENCES LLC | 2021-05-20 | — | — | US | disclosed |
| EP-3808348-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) | Biogen MA Inc. (US) | 2021-04-21 | — | — | EP | disclosed |
| WO-2011029053-A1 | HUMAN EMBRYONIC STEM CELLS FOR HIGH THROUGHOUT DRUG SCREENING | BUCK INSTITUTE FOR AGE RESEARCH (US) | 2011-03-10 | — | — | WO | disclosed |
| EP-2200611-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) | Biogen Idec MA, Inc. (US) | 2010-06-30 | — | — | EP | disclosed |
| US-20090143279-A1 | Methods and compositions for treating metabolic disorders | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2009-06-04 | — | — | US | disclosed |
| WO-2009038684-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) | BIOGEN IDEC MA INC. (US) | 2009-03-26 | — | — | WO | disclosed |
| WO-2008156654-A2 | CYTOSKELETON MODULATORS FOR TREATING METABOLIC DISORDERS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2007086663-A1 | HIF-1 ALPHA ACTIVATING AGENT | UNIVERSITY OF SEOUL FOUNDATION OF INDUSTRIAL AND ACADEMIC COOPERATION (KR) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143279-A1 | Methods and compositions for treating metabolic disorders | PC, PCK2, CS | MGAM 824/4885MAPT 357/4885ALDH1A1 860/4885 |
| US-20210144998-A1 | COMPOSITIONS AND METHODS FOR TREATING HUANGLONGBING DISEASE IN CITRUS | PNPO, G6PD, AGXT | MGAM 10/4885MAPT 508/4885ALDH1A1 2196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.